25 XP   0   0   10

Helix BioPharma Corp.
Buy, Hold or Sell?

Let's analyse Helix BioPharma Corp. together

PenkeI guess you are interested in Helix BioPharma Corp.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Helix BioPharma Corp.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Helix BioPharma Corp.

I send you an email if I find something interesting about Helix BioPharma Corp..

Quick analysis of Helix BioPharma Corp. (30 sec.)










What can you expect buying and holding a share of Helix BioPharma Corp.? (30 sec.)

How much money do you get?

How much money do you get?
C$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
C$0.00
Expected worth in 1 year
C$0.01
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
C$0.01
Return On Investment
3.9%

For what price can you sell your share?

Current Price per Share
C$0.18
Expected price per share
C$0.17 - C$0.22
How sure are you?
50%

1. Valuation of Helix BioPharma Corp. (5 min.)




Live pricePrice per Share (EOD)

C$0.18

Intrinsic Value Per Share

C$-0.21 - C$0.02

Total Value Per Share

C$-0.21 - C$0.03

2. Growth of Helix BioPharma Corp. (5 min.)




Is Helix BioPharma Corp. growing?

Current yearPrevious yearGrowGrow %
How rich?$451.8k-$797.9k$1.3m250.7%

How much money is Helix BioPharma Corp. making?

Current yearPrevious yearGrowGrow %
Making money-$1m-$1m-$36.3k-3.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Helix BioPharma Corp. (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#862 / 1016

Most Revenue
#968 / 1016

Most Profit
#242 / 1016

Most Efficient
#421 / 1016

What can you expect buying and holding a share of Helix BioPharma Corp.? (5 min.)

Welcome investor! Helix BioPharma Corp.'s management wants to use your money to grow the business. In return you get a share of Helix BioPharma Corp..

What can you expect buying and holding a share of Helix BioPharma Corp.?

First you should know what it really means to hold a share of Helix BioPharma Corp.. And how you can make/lose money.

Speculation

The Price per Share of Helix BioPharma Corp. is C$0.175. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Helix BioPharma Corp..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Helix BioPharma Corp., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is C$0.00. Based on the TTM, the Book Value Change Per Share is C$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is C$0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is C$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Helix BioPharma Corp..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 C$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per Share
Usd Eps0.00-2.4%-0.01-3.6%-0.01-3.0%-0.01-3.7%-0.01-4.0%
Usd Book Value Change Per Share0.002.8%0.000.7%0.001.5%0.000.2%0.00-0.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.002.8%0.000.7%0.001.5%0.000.2%0.00-0.2%
Usd Price Per Share0.16-0.16-0.16-0.42-0.73-
Price to Earnings Ratio-9.50--6.89--7.37--17.99--26.57-
Price-to-Total Gains Ratio32.52--3.16-1.36--32.90--398.18-
Price to Book Ratio76.64-23.50-5.82-62.13--230.63-
Price-to-Total Gains Ratio32.52--3.16-1.36--32.90--398.18-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.12712
Number of shares7866
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (7866 shares)9.803.04
Gains per Year (7866 shares)39.2112.17
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1039290122
20786802414
3011810703726
4015714604938
5019618506150
6023522407362
7027426308574
8031430209786
90353341011098
1003923800122110

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%1.053.00.01.9%
Book Value Change Per Share2.02.00.050.0%5.06.01.041.7%9.010.01.045.0%14.025.01.035.0%17.032.05.031.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.054.00.0%
Total Gains per Share2.02.00.050.0%5.06.01.041.7%9.010.01.045.0%14.025.01.035.0%17.032.05.031.5%

Fundamentals of Helix BioPharma Corp.

About Helix BioPharma Corp.

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Fundamental data was last updated by Penke on 2024-04-10 05:44:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Helix BioPharma Corp..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Helix BioPharma Corp. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Helix BioPharma Corp. to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Helix BioPharma Corp.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-546.8%+546.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY--279.3%+279.3%
5Y--436.8%+436.8%
10Y-546.8%-599.3%+52.5%
1.1.2. Return on Assets

Shows how efficient Helix BioPharma Corp. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Helix BioPharma Corp. to the Biotechnology industry mean.
  • -66.2% Return on Assets means that Helix BioPharma Corp. generated $-0.66 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Helix BioPharma Corp.:

  • The MRQ is -66.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -98.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-66.2%TTM-98.9%+32.8%
TTM-98.9%YOY-46.6%-52.4%
TTM-98.9%5Y-84.5%-14.4%
5Y-84.5%10Y-79.8%-4.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-66.2%-13.6%-52.6%
TTM-98.9%-12.9%-86.0%
YOY-46.6%-11.9%-34.7%
5Y-84.5%-14.2%-70.3%
10Y-79.8%-16.2%-63.6%
1.1.3. Return on Equity

Shows how efficient Helix BioPharma Corp. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Helix BioPharma Corp. to the Biotechnology industry mean.
  • -201.6% Return on Equity means Helix BioPharma Corp. generated $-2.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Helix BioPharma Corp.:

  • The MRQ is -201.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -99.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-201.6%TTM-99.9%-101.7%
TTM-99.9%YOY-108.7%+8.8%
TTM-99.9%5Y-431.5%+331.6%
5Y-431.5%10Y-282.4%-149.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-201.6%-17.0%-184.6%
TTM-99.9%-16.1%-83.8%
YOY-108.7%-15.4%-93.3%
5Y-431.5%-20.0%-411.5%
10Y-282.4%-21.1%-261.3%

1.2. Operating Efficiency of Helix BioPharma Corp..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Helix BioPharma Corp. is operating .

  • Measures how much profit Helix BioPharma Corp. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Helix BioPharma Corp. to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Helix BioPharma Corp.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-546.2%+546.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY--288.4%+288.4%
5Y--475.2%+475.2%
10Y-546.2%-624.7%+78.5%
1.2.2. Operating Ratio

Measures how efficient Helix BioPharma Corp. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Helix BioPharma Corp.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y5.636-5.636
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY-3.766-3.766
5Y-5.675-5.675
10Y5.6367.857-2.221

1.3. Liquidity of Helix BioPharma Corp..

1.3. Liquidity
1.3.1. Current Ratio

Measures if Helix BioPharma Corp. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.46 means the company has $1.46 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Helix BioPharma Corp.:

  • The MRQ is 1.456. The company is just able to pay all its short-term debts.
  • The TTM is 1.884. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.456TTM1.884-0.427
TTM1.884YOY0.828+1.056
TTM1.8845Y1.508+0.376
5Y1.50810Y2.219-0.712
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4563.930-2.474
TTM1.8844.251-2.367
YOY0.8285.436-4.608
5Y1.5086.045-4.537
10Y2.2196.363-4.144
1.3.2. Quick Ratio

Measures if Helix BioPharma Corp. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Helix BioPharma Corp. to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Helix BioPharma Corp.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.404-1.404
TTM1.404YOY0.796+0.608
TTM1.4045Y1.268+0.136
5Y1.26810Y2.052-0.784
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.629-3.629
TTM1.4044.065-2.661
YOY0.7965.397-4.601
5Y1.2685.993-4.725
10Y2.0526.277-4.225

1.4. Solvency of Helix BioPharma Corp..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Helix BioPharma Corp. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Helix BioPharma Corp. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.67 means that Helix BioPharma Corp. assets are financed with 67.2% credit (debt) and the remaining percentage (100% - 67.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Helix BioPharma Corp.:

  • The MRQ is 0.672. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.805. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.672TTM0.805-0.133
TTM0.805YOY1.436-0.630
TTM0.8055Y1.325-0.520
5Y1.32510Y1.076+0.249
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6720.332+0.340
TTM0.8050.334+0.471
YOY1.4360.268+1.168
5Y1.3250.366+0.959
10Y1.0760.390+0.686
1.4.2. Debt to Equity Ratio

Measures if Helix BioPharma Corp. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Helix BioPharma Corp. to the Biotechnology industry mean.
  • A Debt to Equity ratio of 204.7% means that company has $2.05 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Helix BioPharma Corp.:

  • The MRQ is 2.047. The company is just not able to pay all its debts with equity.
  • The TTM is 0.805. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ2.047TTM0.805+1.241
TTM0.805YOY2.673-1.868
TTM0.8055Y4.091-3.286
5Y4.09110Y2.590+1.500
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0470.381+1.666
TTM0.8050.390+0.415
YOY2.6730.334+2.339
5Y4.0910.434+3.657
10Y2.5900.466+2.124

2. Market Valuation of Helix BioPharma Corp.

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Helix BioPharma Corp. generates.

  • Above 15 is considered overpriced but always compare Helix BioPharma Corp. to the Biotechnology industry mean.
  • A PE ratio of -9.50 means the investor is paying $-9.50 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Helix BioPharma Corp.:

  • The EOD is -7.559. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.503. Based on the earnings, the company is expensive. -2
  • The TTM is -6.888. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.559MRQ-9.503+1.944
MRQ-9.503TTM-6.888-2.616
TTM-6.888YOY-7.368+0.481
TTM-6.8885Y-17.986+11.098
5Y-17.98610Y-26.574+8.588
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.559-2.315-5.244
MRQ-9.503-2.560-6.943
TTM-6.888-2.664-4.224
YOY-7.368-4.122-3.246
5Y-17.986-6.258-11.728
10Y-26.574-6.108-20.466
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Helix BioPharma Corp.:

  • The EOD is -5.086. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.393. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.053. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.086MRQ-6.393+1.308
MRQ-6.393TTM-8.053+1.660
TTM-8.053YOY-7.313-0.740
TTM-8.0535Y-17.191+9.138
5Y-17.19110Y-28.955+11.764
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.086-3.067-2.019
MRQ-6.393-3.251-3.142
TTM-8.053-3.545-4.508
YOY-7.313-5.595-1.718
5Y-17.191-8.315-8.876
10Y-28.955-8.708-20.247
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Helix BioPharma Corp. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 76.64 means the investor is paying $76.64 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Helix BioPharma Corp.:

  • The EOD is 60.961. Based on the equity, the company is expensive. -2
  • The MRQ is 76.637. Based on the equity, the company is expensive. -2
  • The TTM is 23.499. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD60.961MRQ76.637-15.676
MRQ76.637TTM23.499+53.138
TTM23.499YOY5.817+17.682
TTM23.4995Y62.131-38.632
5Y62.13110Y-230.627+292.758
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD60.9611.905+59.056
MRQ76.6372.111+74.526
TTM23.4992.095+21.404
YOY5.8172.836+2.981
5Y62.1313.443+58.688
10Y-230.6273.794-234.421
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Helix BioPharma Corp. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0070.002+294%0.004+82%0.001+1170%-0.001+107%
Book Value Per Share--0.0030.003-15%-0.005+277%0.001+177%0.005-46%
Current Ratio--1.4561.884-23%0.828+76%1.508-3%2.219-34%
Debt To Asset Ratio--0.6720.805-17%1.436-53%1.325-49%1.076-38%
Debt To Equity Ratio--2.0470.805+154%2.673-23%4.091-50%2.590-21%
Dividend Per Share----0%-0%-0%-0%
Eps---0.006-0.009+50%-0.007+27%-0.009+55%-0.010+67%
Free Cash Flow Per Share---0.009-0.007-19%-0.007-13%-0.009+2%-0.009+6%
Free Cash Flow To Equity Per Share--0.0040.002+138%0.006-39%0.002+79%0.003+41%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.024--------
Intrinsic Value_10Y_min---0.215--------
Intrinsic Value_1Y_max---0.025--------
Intrinsic Value_1Y_min---0.034--------
Intrinsic Value_3Y_max---0.054--------
Intrinsic Value_3Y_min---0.092--------
Intrinsic Value_5Y_max---0.058--------
Intrinsic Value_5Y_min---0.139--------
Market Cap37917950.000-26%47668371.30046584932.825+2%46584910.000+2%124370880.565-62%218678236.783-78%
Net Profit Margin----0%-0%-0%-5.4680%
Operating Margin----0%-0%-0%-5.4620%
Operating Ratio----0%-0%-0%5.636-100%
Pb Ratio60.961-26%76.63723.499+226%5.817+1217%62.131+23%-230.627+401%
Pe Ratio-7.559+20%-9.503-6.888-28%-7.368-22%-17.986+89%-26.574+180%
Price Per Share0.175-26%0.2200.215+2%0.215+2%0.574-62%1.009-78%
Price To Free Cash Flow Ratio-5.086+20%-6.393-8.053+26%-7.313+14%-17.191+169%-28.955+353%
Price To Total Gains Ratio25.865-26%32.516-3.164+110%1.360+2292%-32.899+201%-398.176+1325%
Quick Ratio---1.404-100%0.796-100%1.268-100%2.052-100%
Return On Assets---0.662-0.989+49%-0.466-30%-0.845+28%-0.798+21%
Return On Equity---2.016-0.999-50%-1.087-46%-4.315+114%-2.824+40%
Total Gains Per Share--0.0070.002+294%0.004+82%0.001+1170%-0.001+107%
Usd Book Value--451820.800529364.000-15%-797950.400+277%163258.400+177%839246.240-46%
Usd Book Value Change Per Share--0.0050.001+294%0.003+82%0.000+1170%0.000+107%
Usd Book Value Per Share--0.0020.002-15%-0.004+277%0.001+177%0.004-46%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.004-0.006+50%-0.005+27%-0.007+55%-0.007+67%
Usd Free Cash Flow---1354009.600-1090508.000-19%-1171864.800-13%-1386407.040+2%-1433695.680+6%
Usd Free Cash Flow Per Share---0.006-0.005-19%-0.005-13%-0.006+2%-0.007+6%
Usd Free Cash Flow To Equity Per Share--0.0030.001+138%0.004-39%0.002+79%0.002+41%
Usd Market Cap27543598.880-26%34626304.91233839295.204+2%33839278.624+2%90343007.642-62%158847871.199-78%
Usd Price Per Share0.127-26%0.1600.156+2%0.156+2%0.417-62%0.733-78%
Usd Profit---910905.600-1070168.800+17%-1033848.800+13%-1367774.880+50%-1490772.560+64%
Usd Revenue----0%-0%-0%980.640-100%
Usd Total Gains Per Share--0.0050.001+294%0.003+82%0.000+1170%0.000+107%
 EOD+2 -6MRQTTM+16 -13YOY+18 -115Y+21 -810Y+19 -12

3.2. Fundamental Score

Let's check the fundamental score of Helix BioPharma Corp. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.559
Price to Book Ratio (EOD)Between0-160.961
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than11.456
Debt to Asset Ratio (MRQ)Less than10.672
Debt to Equity Ratio (MRQ)Less than12.047
Return on Equity (MRQ)Greater than0.15-2.016
Return on Assets (MRQ)Greater than0.05-0.662
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Helix BioPharma Corp. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.703
Ma 20Greater thanMa 500.185
Ma 50Greater thanMa 1000.184
Ma 100Greater thanMa 2000.201
OpenGreater thanClose0.180
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-10-31. Currency in CAD. All numbers in thousands.

Summary
Total Assets1,895
Total Liabilities1,273
Total Stockholder Equity622
 As reported
Total Liabilities 1,273
Total Stockholder Equity+ 622
Total Assets = 1,895

Assets

Total Assets1,895
Total Current Assets1,854
Long-term Assets41
Total Current Assets
Cash And Cash Equivalents 1,641
Total Current Assets  (as reported)1,854
Total Current Assets  (calculated)1,641
+/- 213
Long-term Assets
Property Plant Equipment 41
Long-term Assets  (as reported)41
Long-term Assets  (calculated)41
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,273
Long-term Liabilities0
Total Stockholder Equity622
Total Current Liabilities
Accounts payable 1,273
Total Current Liabilities  (as reported)1,273
Total Current Liabilities  (calculated)1,273
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)622
Total Stockholder Equity (calculated)0
+/- 622
Other
Capital Stock154,754
Common Stock Shares Outstanding 216,674
Net Invested Capital 622
Net Working Capital 581



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2023-10-312023-07-312023-04-302023-01-312022-10-312022-07-312022-04-302022-01-312021-10-312021-07-312021-04-302021-01-312020-10-312020-07-312020-04-302020-01-312019-10-312019-07-312019-04-302019-01-312018-10-312018-07-312018-04-302018-01-312017-10-312017-07-312017-04-302017-01-312016-10-312016-07-312016-04-302016-01-312015-10-312015-07-312015-04-302015-01-312014-10-312014-07-312014-04-302014-01-312013-10-312013-07-312013-04-302013-01-312012-10-312012-07-312012-04-302012-01-312011-10-312011-07-312011-04-302011-01-312010-10-312010-07-31
> Total Assets 
0
0
0
0
24,371
16,021
10,002
7,616
5,828
10,265
8,151
5,868
3,690
5,518
3,663
7,853
5,593
3,561
9,997
7,796
5,692
3,271
5,583
4,468
3,248
2,493
2,269
2,187
4,095
2,653
1,714
1,147
1,780
1,195
1,599
940
2,435
2,739
5,561
4,906
4,578
5,001
3,023
4,065
3,730
944
2,335
2,335
3,730
4,801
3,197
1,586
1,029
1,895
1,8951,0291,5863,1974,8013,7302,3352,3359443,7304,0653,0235,0014,5784,9065,5612,7392,4359401,5991,1951,7801,1471,7142,6534,0952,1872,2692,4933,2484,4685,5833,2715,6927,7969,9973,5615,5937,8533,6635,5183,6905,8688,15110,2655,8287,61610,00216,02124,3710000
   > Total Current Assets 
0
0
0
0
21,680
13,660
8,191
6,123
4,425
8,964
6,945
5,191
3,067
4,942
3,138
7,405
5,174
3,175
9,642
7,467
5,371
2,984
5,331
4,233
2,936
2,065
1,774
1,700
3,640
2,229
1,306
773
1,434
883
1,316
687
2,199
2,524
5,453
4,660
4,408
4,874
2,936
4,018
3,695
902
2,297
2,297
3,695
4,762
3,158
1,551
996
1,854
1,8549961,5513,1584,7623,6952,2972,2979023,6954,0182,9364,8744,4084,6605,4532,5242,1996871,3168831,4347731,3062,2293,6401,7001,7742,0652,9364,2335,3312,9845,3717,4679,6423,1755,1747,4053,1384,9423,0675,1916,9458,9644,4256,1238,19113,66021,6800000
       Cash And Cash Equivalents 
0
0
0
0
19,044
11,919
5,867
4,862
4,493
8,478
6,674
4,493
6,980
4,386
2,832
6,980
6,792
2,723
9,151
6,792
3,654
2,523
4,929
3,654
897
1,423
1,323
897
366
1,641
770
366
206
306
938
206
4,235
2,094
4,989
4,235
3,565
4,098
2,266
3,565
3,252
471
1,882
1,882
3,252
4,397
2,824
1,330
808
1,641
1,6418081,3302,8244,3973,2521,8821,8824713,2523,5652,2664,0983,5654,2354,9892,0944,2352069383062063667701,6413668971,3231,4238973,6544,9292,5233,6546,7929,1512,7236,7926,9802,8324,3866,9804,4936,6748,4784,4934,8625,86711,91919,0440000
       Net Receivables 
0
0
0
0
1,906
950
1,738
733
666
271
117
559
474
348
183
343
328
271
266
491
278
248
242
489
485
477
332
630
409
417
362
315
241
246
158
290
199
172
196
180
166
390
392
353
280
319
349
349
279
149
105
114
62
0
0621141051492793493493192803533923901661801961721992901582462413153624174096303324774854892422482784912662713283431833484745591172716667331,7389501,9060000
       Other Current Assets 
0
0
0
0
202
286
130
107
141
215
154
139
111
208
123
82
32
181
225
184
85
213
160
90
54
165
119
173
56
171
174
92
322
331
220
191
350
258
268
245
2,814
386
278
100
-1
112
66
163
-1
-38
229
0
0
0
000229-38-116366112-11002783862,814245268258350191220331322921741715617311916554901602138518422518132821232081111391542151411071302862020000
   > Long-term Assets 
0
0
0
0
2,691
2,361
1,811
1,493
1,403
1,301
1,206
677
623
576
525
448
419
386
355
329
321
287
252
235
312
428
495
487
455
424
408
374
346
312
283
253
236
215
108
246
170
127
87
47
35
41
37
37
36
39
39
36
33
41
4133363939363737413547871271702461082152362532833123463744084244554874954283122352522873213293553864194485255766236771,2061,3011,4031,4931,8112,3612,6910000
       Property Plant Equipment 
0
0
0
0
2,031
1,874
1,546
1,049
959
857
762
677
623
576
525
448
419
386
355
329
321
287
252
235
312
428
495
487
455
424
408
374
346
312
283
253
236
215
108
246
170
127
87
47
35
41
37
37
36
38
39
36
33
41
4133363938363737413547871271702461082152362532833123463744084244554874954283122352522873213293553864194485255766236777628579591,0491,5461,8742,0310000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
3
3
3
3
1
1
199
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000019911333350000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
-1
0
0
-1
0
0
00-100-1111000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
0
2,258
5,276
1,886
1,392
1,585
1,277
1,319
948
879
514
650
1,042
803
1,174
1,125
969
1,368
1,004
1,446
1,304
2,341
2,676
3,768
2,204
1,966
2,492
3,221
2,674
3,431
2,881
3,519
4,221
1,769
1,651
1,627
1,925
1,982
1,235
1,713
5,458
3,411
5,036
4,259
4,259
3,411
5,666
973
673
1,873
1,273
1,2731,8736739735,6663,4114,2594,2595,0363,4115,4581,7131,2351,9821,9251,6271,6511,7694,2213,5192,8813,4312,6743,2212,4921,9662,2043,7682,6762,3411,3041,4461,0041,3689691,1251,1748031,0426505148799481,3191,2771,5851,3921,8865,2762,2580000
   > Total Current Liabilities 
0
0
0
0
2,210
5,241
1,857
1,369
1,568
1,267
1,315
948
879
514
650
1,042
803
1,174
1,125
969
1,368
1,004
1,446
1,304
2,341
2,677
3,768
2,204
1,966
2,492
3,221
2,674
3,431
2,881
3,519
4,221
1,769
1,651
1,627
1,925
1,982
1,235
1,713
3,874
3,411
4,012
3,312
3,312
3,411
5,666
973
674
1,874
1,273
1,2731,8746749735,6663,4113,3123,3124,0123,4113,8741,7131,2351,9821,9251,6271,6511,7694,2213,5192,8813,4312,6743,2212,4921,9662,2043,7682,6772,3411,3041,4461,0041,3689691,1251,1748031,0426505148799481,3151,2671,5681,3691,8575,2412,2100000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
159
0
0
159
99
67
34
2,028
2,468
1,940
1,935
1,935
0
0
0
0
0
0
0000001,9351,9351,9402,4682,02834679915900159000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,028
2,037
1,940
1,935
2,468
0
0
0
0
0
000002,4681,9351,9402,0372,02800000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
1,085
844
1,140
650
744
652
799
304
554
218
246
566
248
514
502
262
770
389
816
715
1,418
1,739
2,123
1,438
1,298
1,752
2,646
1,992
2,968
2,378
2,801
3,040
1,510
1,094
1,090
1,416
1,685
841
1,265
1,466
599
1,579
927
927
599
660
707
391
493
1,273
1,2734933917076605999279271,5795991,4661,2658411,6851,4161,0901,0941,5103,0402,8012,3782,9681,9922,6461,7521,2981,4382,1231,7391,4187158163897702625025142485662462185543047996527446501,1408441,0850000
       Other Current Liabilities 
0
0
0
0
1,125
4,397
717
719
824
615
516
644
325
296
404
476
555
660
623
707
598
615
630
589
879
938
1,645
722
585
696
534
644
433
446
667
1,057
37
473
453
350
198
327
414
380
344
493
450
450
-1
5,006
266
0
998
0
099802665,006-1450450493344380414327198350453473371,0576674464336445346965857221,6459388795896306155987076236605554764042963256445166158247197174,3971,1250000
   > Long-term Liabilities 
0
0
0
0
48
35
29
23
17
10
4
4
554
218
246
566
248
514
502
262
770
389
816
715
1,462
-1
-1
1,482
1,381
1,796
2,687
2,030
2,998
2,435
2,852
3,164
1,732
1,178
1,174
1,575
1,584
908
1,299
1,584
1,281
1,024
947
947
0
707
707
-1
-1
0
0-1-170770709479471,0241,2811,5841,2999081,5841,5751,1741,1781,7323,1642,8522,4352,9982,0302,6871,7961,3811,482-1-11,462715816389770262502514248566246218554441017232935480000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,584
1,281
1,024
947
0
0
0
0
0
0
0000009471,0241,2811,58400000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
0
22,113
10,745
8,116
6,224
4,243
8,988
6,832
4,920
2,811
5,004
3,013
6,811
4,790
2,387
8,872
6,827
4,324
2,267
4,137
3,164
907
-183
-1,499
-17
2,129
161
-1,507
-1,527
-1,651
-1,686
-1,920
-3,281
45
115
4,788
2,394
2,596
3,766
1,310
-1,393
319
-4,092
-1,924
-1,924
319
-865
2,224
913
-844
622
622-8449132,224-865319-1,924-1,924-4,092319-1,3931,3103,7662,5962,3944,78811545-3,281-1,920-1,686-1,651-1,527-1,5071612,129-17-1,499-1839073,1644,1372,2674,3246,8278,8722,3874,7906,8113,0135,0042,8114,9206,8328,9884,2436,2248,11610,74522,1130000
   Common Stock
0
0
0
0
0
0
0
0
101,407
102,393
102,393
101,407
100,741
103,584
103,584
107,079
107,079
107,186
112,288
112,288
112,307
112,461
115,074
116,146
116,988
117,944
118,969
120,681
123,691
124,099
124,436
125,565
126,505
127,940
129,188
129,532
132,984
134,381
137,257
137,257
137,257
139,660
139,660
139,660
147,511
140,483
143,916
143,916
147,511
147,916
152,068
152,068
152,068
0
0152,068152,068152,068147,916147,511143,916143,916140,483147,511139,660139,660139,660137,257137,257137,257134,381132,984129,532129,188127,940126,505125,565124,436124,099123,691120,681118,969117,944116,988116,146115,074112,461112,307112,288112,288107,186107,079107,079103,584103,584100,741101,407102,393102,393101,40700000000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000-1,761-1,761-1,757-1,740-2,069-2,551-2,443-2,407-2,390-2,358-2,329-2,300-2,265-2,215-2,190-157,683-2,099-2,053-2,251-2,099-3,348-3,319-3,250-3,250-3,214-3,151-3,116-3,116-3,081-3,004-2,953-3,081-2,849-2,764-2,665-3,118-3,01500-2,0960000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,179
23,179
23,315
23,315
23,535
25,945
25,540
27,141
27,201
27,331
27,867
27,867
27,867
29,993
37,590
38,563
40,160
41,787
44,137
0
044,13741,78740,16038,56337,59029,99327,86727,86727,86727,33127,20127,14125,54025,94523,53523,31523,31523,17923,1790000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
122,820
113,265
122,960
125,938
24,730
23,367
23,534
24,606
25,532
27,386
27,555
29,739
29,878
30,033
30,121
33,409
33,515
33,530
35,099
35,687
34,626
35,350
35,725
36,781
200,126
38,500
38,667
39,178
39,528
39,995
40,613
41,108
43,175
44,115
48,509
47,722
47,817
49,093
49,195
49,262
47,925
47,811
47,891
47,891
10,335
47,942
48,064
6,312
0
0
006,31248,06447,94210,33547,89147,89147,81147,92549,26249,19549,09347,81747,72248,50944,11543,17541,10840,61339,99539,52839,17838,66738,500200,12636,78135,72535,35034,62635,68735,09933,53033,51533,40930,12130,03329,87829,73927,55527,38625,53224,60623,53423,36724,730125,938122,960113,265122,8200000



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

Currency in CAD. All numbers in thousands.




Income Statement

Currency in CAD. All numbers in thousands.


Latest Income Statement (annual, 2023-07-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-6,326
Operating Income-6,326-6,326
 
Operating Expense (+$)
Research Development5,281
Selling General Administrative1,045
Selling And Marketing Expenses0
Operating Expense6,3266,326
 
Net Interest Income (+$)
Interest Income31
Interest Expense-14
Other Finance Cost-16
Net Interest Income33
 
Pretax Income (+$)
Operating Income-6,326
Net Interest Income33
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-6,290-6,329
EBIT - interestExpense = -14
-6,290
-6,276
Interest Expense14
Earnings Before Interest and Taxes (EBIT)0-6,276
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-6,290
Tax Provision-0
Net Income From Continuing Ops-6,290-6,290
Net Income-6,290
Net Income Applicable To Common Shares-6,290
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net3-33
 

Technical Analysis of Helix BioPharma Corp.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Helix BioPharma Corp.. The general trend of Helix BioPharma Corp. is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Helix BioPharma Corp.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Helix BioPharma Corp..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.21 < 0.21 < 0.22.

The bearish price targets are: 0.17 > 0.17 > 0.17.

Tweet this
Helix BioPharma Corp. Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Helix BioPharma Corp.. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Helix BioPharma Corp. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Helix BioPharma Corp.. The current macd is -0.00074143.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Helix BioPharma Corp. price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Helix BioPharma Corp.. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Helix BioPharma Corp. price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Helix BioPharma Corp. Daily Moving Average Convergence/Divergence (MACD) ChartHelix BioPharma Corp. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Helix BioPharma Corp.. The current adx is 20.81.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Helix BioPharma Corp. shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Helix BioPharma Corp. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Helix BioPharma Corp.. The current sar is 0.21568774.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Helix BioPharma Corp. Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Helix BioPharma Corp.. The current rsi is 43.70. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Helix BioPharma Corp. Daily Relative Strength Index (RSI) ChartHelix BioPharma Corp. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Helix BioPharma Corp.. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Helix BioPharma Corp. price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Helix BioPharma Corp. Daily Stochastic Oscillator ChartHelix BioPharma Corp. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Helix BioPharma Corp.. The current cci is -72.39819005.

Helix BioPharma Corp. Daily Commodity Channel Index (CCI) ChartHelix BioPharma Corp. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Helix BioPharma Corp.. The current cmo is -16.98109378.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Helix BioPharma Corp. Daily Chande Momentum Oscillator (CMO) ChartHelix BioPharma Corp. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Helix BioPharma Corp.. The current willr is -70.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Helix BioPharma Corp. is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Helix BioPharma Corp. Daily Williams %R ChartHelix BioPharma Corp. Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Helix BioPharma Corp..

Helix BioPharma Corp. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Helix BioPharma Corp.. The current atr is 0.0099552.

Helix BioPharma Corp. Daily Average True Range (ATR) ChartHelix BioPharma Corp. Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Helix BioPharma Corp.. The current obv is 666,499.

Helix BioPharma Corp. Daily On-Balance Volume (OBV) ChartHelix BioPharma Corp. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Helix BioPharma Corp.. The current mfi is 23.44.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Helix BioPharma Corp. Daily Money Flow Index (MFI) ChartHelix BioPharma Corp. Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Helix BioPharma Corp..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Helix BioPharma Corp. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Helix BioPharma Corp. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.703
Ma 20Greater thanMa 500.185
Ma 50Greater thanMa 1000.184
Ma 100Greater thanMa 2000.201
OpenGreater thanClose0.180
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Helix BioPharma Corp. with someone you think should read this too:
  • Are you bullish or bearish on Helix BioPharma Corp.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Helix BioPharma Corp.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Helix BioPharma Corp.

I send you an email if I find something interesting about Helix BioPharma Corp..


Comments

How you think about this?

Leave a comment

Stay informed about Helix BioPharma Corp..

Receive notifications about Helix BioPharma Corp. in your mailbox!